In 1999, when I started Asymchem with a single laboratory in North Carolina’s Research Triangle Park (RTP), I did it with not much more than my unbridled enthusiasm for chemistry. Fortunately this period of steadfast faith in therapeutics coincided with the budding Chinese CDMO industry. In 2000, through careful consideration and investment, Asymchem extended its fast-growing operations to China and the story began to unfold.
Today Asymchem employs more than 5500 people at eight sites and count as our clients as the world’s top pharmaceutical companies. While I’m proud of such a significant accomplishment, our numerous advances in novel technology including the commercial-sized application of flow chemistry in API manufacturing, have fueled my continued passion for chemistry. Along with the recent construction of Asymchem’s multidimensional service platform, we’ve realized that our enriched expertise and commitment to innovation can extend beyond “big pharma” to those newly emerged biotech labs and even smaller sized specialty pharmaceutical companies adopting cutting-edge therapeutics. Using the “Know How” spirit, Asymchem has made it our mission to help these innovators successfully bring their products to market.
Dr. Hao Hong
Advisory Board of Pharmaceutical Development Strategy
With the establishment of a pharmaceutical development strategy expert committee, Asymchem’s Board of Pharmaceutical Development Strategy aims to expand the company’s China market. By leveraging experts and scholars, we’ve been able to create a valuable intellectual synergy, actively promote Asymchem’s green pharmaceutical technology progress, and improve the professionalism and scientific level of strategic decisions.